



(11) **EP 2 383 034 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention  
of the grant of the patent:  
**13.08.2014 Bulletin 2014/33**

(51) Int Cl.:  
**A61K 9/51** (2006.01) **A61K 9/14** (2006.01)  
**B01D 11/00** (2006.01) **B01J 13/00** (2006.01)  
**B01F 3/00** (2006.01)

(21) Application number: **09836113.2**

(86) International application number:  
**PCT/ES2009/070485**

(22) Date of filing: **06.11.2009**

(87) International publication number:  
**WO 2010/076360 (08.07.2010 Gazette 2010/27)**

(54) **METHOD FOR OBTAINING SOLID MICRO- OR NANOPARTICLES**

VERFAHREN ZUM ERHALT VON FESTEN MIKRO- ODER NANOTEILCHEN

PROCÉDÉ POUR OBTENIR DES MICROPARTICULES OU DES NANOPARTICULES SOLIDES

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL  
PT RO SE SI SK SM TR**

- **VECIANA MIRÓ, Jaume**  
E-08193 Bellaterra (Barcelona) (ES)
- **CANO SARABIA, Mary**  
E-08193 Bellaterra (Barcelona) (ES)
- **SALA VERGÉS, Santiago**  
E-08193 Bellaterra (Barcelona) (ES)

(30) Priority: **30.12.2008 ES 200803753**

(43) Date of publication of application:  
**02.11.2011 Bulletin 2011/44**

(74) Representative: **Oficina Ponti, SLP**  
**C. Consell de Cent, 322**  
**08007 Barcelona (ES)**

(73) Proprietors:

- **Consejo Superior de Investigaciones Científicas (CSIC)**  
**28006 Madrid (ES)**
- **Centro De Investigación Biomédica En Red En Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN)**  
**50018 Zaragoza (ES)**

(56) References cited:  
**WO-A1-02/16003 WO-A1-2006/079889**  
**WO-A2-2007/009986 ES-A1- 2 170 008**  
**ES-A1- 2 265 262 ES-A1- 2 292 300**  
**ES-T3- 2 228 149 ES-T3- 2 261 469**  
**US-A1- 2001 055 561 US-A1- 2004 076 670**

(72) Inventors:

- **VENTOSA RULL, Nora**  
E-08193 Bellaterra (Barcelona) (ES)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 2 383 034 B1**

## Description

### FIELD OF THE INVENTION

**[0001]** This invention provides a process to obtain solid micro- or nanoparticles with a homogenous structure from a microemulsion.

**[0002]** According to the invention, it provides a process which allows to obtain solid micro- or nanoparticles of a homogenous structure, with a size of a particles of less than 10  $\mu\text{m}$  in which the solid processed compound reveals the nature, e.g., crystalline, amorphous, polymorphic, etc..., typical of the original compound. According to the invention process, sizes as small as 500 nm can be obtained. Advantageously, the invention provides a process to obtain for obtaining solid micro-or nanoparticles with an aspect ratio close to the unity (1), i.e., with a substantially spheroidal morphology.

### BACKGROUND OF THE INVENTION

**[0003]** There are in the state of the art different processes that refer to obtaining particles finely divided as a strategy to increase their water solubility and, therefore, the bioavailability of active molecules in physiological conditions. Some of these processes have used as a model molecule, ibuprofen to show their effectiveness in this way. Below, are some details of the work based on experiments with ibuprofen.

**[0004]** The article by N. Rasenack, B. W. Müller, Pharmaceutical Research, 2002, 19, 1894-1900, proposes the use of a technique called in-situ Micronization as an alternative to the conventional techniques of micronization by grinding to obtain micro- and nanoparticles of solids slightly insoluble in water such as ibuprofen. To form the particulate solid an aqueous solution is poured in a stabilizing agent over a solution of ibuprofen in an organic solvent miscible in water. In this process water acts as a non-solvent of the product causing its precipitation and producing a suspension of it. This precipitation is followed by a process of "spray drying" to eliminate the liquid from said suspension and isolating the particulate solid. This solid consists of microparticles of the active principle coated with the stabilizing agent.

**[0005]** In the article by M. Charoenchaitrakool, F. Deghani, N. R. Foster, Ind. Eng. Chem. Res. 2000, 39, 4794-4802 racemic ibuprofen and S-ibuprofen have been micronized by the RESS process described in patent US 4582731. This process consists in the depressurization of a solution of a product (ibuprofen) in a supercritical fluid ( $\text{CO}_2$ ) through a nozzle, causing its precipitation. Microparticles of the product (1-15  $\mu\text{m}$ ) are obtained with an irregular geometry and with a considerable loss in crystallinity.

**[0006]** In the article by D. Hermsdorf, Stephan Jauer, R. Signorelli, Molecular Physics, 2007, 105, 8, 951-959, racemic ibuprofen and S-ibuprofen have also been micronized using the process RESS. Particles of pure ibu-

profen strongly agglomerated and coagulated which consist of primary particles of 100-500 nm with irregular shapes.

**[0007]** The article by P. Pathak, M.J. Meziani, T. Desai, Y.-p. Sun, J. Supercrit. Fluids, 2006, 37, 279-286 describes how to obtain suspensions in water of not-agglomerated ibuprofen particles at a nanometric scale by using the RESOLV process. This process consists in depressurizing the RESS method over an aqueous solution obtaining the stabilization of particles in the aqueous medium which can contain a surfactant. This process is described in patent applications WO9965469 and WO9714407.

**[0008]** However, it is often desirable to obtain solid particles finely divided with a greater control of the particle size.

**[0009]** Mainly, three methodologies have been developed to prepare finely divided solid particles based on the use of emulsions and  $\text{CO}_2$ .

**[0010]** In the first methodology, the synthesis of the particles is done by an anti-solvent effect of the  $\text{CO}_2$  ("anti-solvent gas", GAS) over an emulsion of the solute to be precipitated. This methodology has been developed by Zhang et al., and comprises two stages: In the first stage, an emulsion of water in a non-polar solvent (usually isooctane) is prepared which contains the solute to be precipitated and a surfactant, both dissolved. The second stage consists in the precipitation of the particles when the emulsion comes into contact with the  $\text{CO}_2$ . This methodology is described, e.g., J. Zhang, B. Han, X. Zhang, J. He, Z. Liu, T. Jiang, G. Yang, Chem Eur. J. 2002, 8, 17, 3879.

**[0011]** The second methodology, called "supercritical fluid extraction emulsion" (SFEE), is based in the precipitation of particles from the extraction by  $\text{CO}_2$  of the non-polar solvent which is a part of the emulsion. This methodology has been developed by "Ferro Corporation" (US2004071781). In this process, the synthesis of the particles also comprises two stages. In the first one, called preparation of the emulsion, the solute to be precipitated is dissolved in a non-polar saturated solvent with water. On the other hand, the surfactant is dissolved in saturated water with the same non-polar solvent. Next, both solutions are mixed to form an emulsion. Finally, the resulting emulsion is homogenized in a homogenizer. In the second stage, the precipitation of the particles takes place. The emulsion is pulverized through a nozzle in an extraction column through which  $\text{CO}_2$  circulates in a counter-current flow. The emulsion droplets come into contact with the  $\text{CO}_2$ , and it extracts the non-polar solvent from the emulsion. The particles will precipitate into fine particles suspended in the aqueous phase. Therefore, through this technology the precipitation of the particles takes place by the extracting effect of the non-polar solvent which causes the precipitation. Within this methodology, based on the extracting role of  $\text{CO}_2$ , *Inserm Inst Nat Sante & Rech Medicale* (WO2007072106) a new process has been developed to prepare the particles.

This process is based in the extraction of the organic solvent of the emulsion by the CO<sub>2</sub>, upon changing it from critical conditions to a liquid state. The particles' synthesis comprises the preparation of an emulsion, and the solidification of the discontinuous phase to form the particles. The emulsion will be made up by a compressed fluid (continuous phase), and a solvent which will contain the solute to be precipitated dissolved (discontinuous phase). The compressed fluid will extract the solvent from the discontinuous phase, upon changing from critical conditions to liquid state, therefore precipitating the particles.

**[0012]** The third particle precipitation methodology is based on the use of emulsions made up of water as a discontinuous medium and CO<sub>2</sub> as the continuous medium ("water-in-CO<sub>2</sub> emulsions"). In this methodology there can be two types of different precipitations. In the first place, there is the one developed by "Ferro Corporation" (WO2004110603) which is based in the pulverization of an emulsion made up of water and CO<sub>2</sub> within a reactor, and a later elimination of the solvents so as to finally obtain the particles. The synthesis comprises three stages. In the first one, an emulsion is prepared. The continuous phase will be made up by compressed fluid or supercritical (CO<sub>2</sub>), and the discontinuous phase by a solution (preferably aqueous) of the solute to be precipitated and/or reacted. In a second stage, the emulsion is pulverized through a nozzle forming small droplets of emulsion. In a third stage, the compressed fluid and the organic solvent from the droplets is eliminated which leads to the precipitation of the particles. In second place is the use of emulsions made up of water as a discontinuous medium and CO<sub>2</sub> as the continuous medium. In this case, the method of precipitation is based in the precipitation of the particles from a mixture of two emulsions water/CO<sub>2</sub>. The synthesis of the particles comprises two stages: In a first stage two emulsions are prepared. The continuous phase is made up of compressed fluid or supercritical (CO<sub>2</sub>), and the discontinuous phase by the solution (preferable aqueous) of the solute to be precipitated and/or reacted. In a second stage, the two emulsions are mixed and their components react precipitating the particles. The article by C.A. Fernandez, C.M. Wai, Small 2006, 2, 11, 1266, describes how to obtain the silver nanoparticles through this methodology.

**[0013]** However, in many occasions it is desirable to obtain solid micro- or nanoparticles with a high homogeneity in the size of the particle and with a greater control of it. Besides, in most existing techniques to date the nature of the initial product does not manifest in the same way in the final processed product, loosing or reducing, e.g., their crystalline nature in the final product.

**[0014]** Therefore, there isn't yet a technology which allows to reduce the size of the particle which allows a greater control and homogeneity of it and which at the same time allows the very own properties, e.g., crystalline, of the nature of the initial product to manifest in the solid micro- or nanoparticles obtained after processing.

## Summarized Description of the invention

**[0015]** To said purpose, this invention provides a process to obtain solid micro- or nanoparticles from a microemulsion. The microemulsions are **characterized in that** they are thermodynamically stable; they form spontaneously with the average diameter of the nanometric droplets and by being transparent or bluish translucent.

**[0016]** The process to obtain the solid micro- or nanoparticles is based on providing a microemulsion which includes water (H<sub>2</sub>O), an organic solvent or a mixture of organic solvents, a solid compound C and a fluid compound B, where said micro- or nanoparticles obtained posses a homogenous structure with a particle size that can reach values as low as 500 nm. According to the invention, the precipitation of the solid micro- or nanoparticles is done by the anti-solvent effect of water without requiring a highly effective agitation system. The process of the invention allows to directly obtain micro- or nanoparticles of a homogenous structure, which manifest the very own properties of the nature of the initial product, e.g., crystallinity, amorphousness, polymorphism, etc..., in the processed product and optionally have an aspect ratio close to the unity (1), i.e., have a substantially spheroidal morphology, and size of particle comprised between 10 μm and 500 nm.

**[0017]** A first aspect of this invention is to provide a new process to obtain solid micro- or nanoparticles of a homogenous structure. Said process comprises preparing a mixture which includes an organic solvent or a mixture of organic solvents, a solid compound C and water (H<sub>2</sub>O), and obtain a microemulsion by adding a fluid B, and increasing the pressure until reaching a first pressure (P<sub>1</sub>) where the predetermined supersaturation value (β) of the solid compound C is lower or equal to 1. Next, a variation of said first pressure (P<sub>1</sub>) to a second pressure (P<sub>2</sub>) allows to modify the solvent effect of water (H<sub>2</sub>O) in said first pressure (P<sub>1</sub>) to an anti-solvent in said second pressure (P<sub>2</sub>) which causes the precipitation of solid micro- or nanoparticles of a homogenous structure; Next, they can be isolated and collected at said second pressure (P<sub>2</sub>) said solid micro- or nanoparticles using conventional methods.

**[0018]** Advantageously, with the process according to the first aspect of the invention micro- or nanoparticles with an improved stability are provided, i.e., with a lower risk of degradation or structural change during their storage, less reactivity and greater stability to mechanical or thermal stress, besides a lower sensibility to humidity.

**[0019]** A second aspect of this invention is the use of said improved micro- or nanoparticles in a composition which also comprises other acceptable pharmaceutical excipients. Advantageously, according to the process other the invention solid micro-or nanoparticles of a homogenous structure, crystalline and with an aspect ratio close to the unity can be obtained, i.e., of a spheroidal morphology, which makes them useful to applications where the structure and morphology of the particles has

a decisive influence for their administration.

[0020] A third aspect of this invention is the use of said micro- or nanoparticles of homogenous structure and with an aspect ratio close to the unity for the preparation of aerosols based on active principles of use via inhalation or for preparing suspensions of a therapeutically active principles which have low hydrosolubility and bioavailability.

#### Definitions

[0021] In this invention, "**fluid B**" refers to a fluid which at atmospheric pressure and room temperature is a gas and which at a first pressure ( $P_1$ ), greater than atmospheric pressure, is miscible with the organic solvent, and immiscible or partially miscible with water. Preferably, said fluid B is selected from  $\text{CO}_2$  and Freon. Besides, according to the pressure and temperature conditions according to the process of the invention said fluid B does not act as a supercritical fluid in any of the stages defined in the attached claims.

[0022] In this invention "**organic solvent**" refers to any polar or apolar organic solvent or mixture of both that is miscible with  $\text{CO}_2$  at a first pressure ( $P_1$ ), higher than the atmospheric pressure, and miscible with water at atmospheric pressure.

[0023] Preferably, said organic solvent can be selected from the group comprised by: monohydric alcohols such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 1-hexanol, 1-octanol and trifluoroethanol, polyhydric alcohols such as propylene glycol, PEG 400, and 1,3-propanediol; ethers such as tetrahydrofuran (THF), and diethyl ether, alkanes such as decalin, isooctane, and mineral oil; aromatics such as benzene, toluene, chlorobenzene, and pyridine, amides such as n-methyl pyrrolidone (NMP), and N,N-dimethylformamide (DMF); esters such as ethyl acetate, propyl acetate, and methyl acetate, 1,2-dichloroethane, and 1,1,1-trichloroethane, ketones such as acetone, methyl ethyl ketone, and Methyl isobutyl ketone; other solvents such as ethylenediamine, acetonitrile, and trimethyl phosphate. Solvents with low volatility such as dimethylacetamide or dimethyl sulfoxide or an ionic liquid can also be used. In an embodiment of the present invention, the preferred organic solvent is acetone.

[0024] In this invention "**surface active agents**" or "surfactant" refers to an anionic, cationic or neutral agents which can be selected among an emulsifying agent, surface agent, stabilizing, protective colloid and, more preferably, from among, the polyethylene glycols (PEGs), the polysorbates, poloxamer, ascorbyl palmitate, lecithin, hexadecyltrimethylammonium bromide (CTAB), sulphates, sulfonates, phosphates, carboxylates, and sulfosuccinates. Yet more preferably, selected from among polyethylene glycols 6000 (PEG6000), bis (2-ethylhexyl) sodium sulfosuccinates (AOT), sodium dodecyl sulphate (SDS), Sodium octyl sulphate, sodium tetradecyl sulphate, octadecyl sodium sulphate, sodium

laurate, cholesterol sulfate sodium salt, sodium dodecyl sulfonate, sodium decyl sulfonate, sodium octyl sulfonate, sodium oleate, as well as among others, or a mixture of thereof.

[0025] In this invention "**aspect ratio**" (RA) refers to a value close to 1, where said value has the sole purpose of defining a particle commonly called of a spheroidal morphology. The aspect ratio can be commonly defined as the relationship between the length and height of the particle, where the length is the greatest distance when measured between two points of the perimeter of the projection of the particle independent of its orientation and width is the greatest distance between two points contained in the intersection of one of the perpendicular axis to the length and perimeter according with the process defined in S.Almeida-Prieto, J. Blanco-Mendez, F.J. Otero-Espinar, European journal of Pharmaceutics and Biopharmaceutics 67 (2007) 766-776, particularly, page 772, Figure 5, process (a), of Research paper "*Microscopic image analysis techniques for the morphological characterization of pharmaceutical particles: influence of the software, and the factor algorithms used in the shape factor estimation*" based on the determination of which the value of the aspect ratio is indicated in this invention, without this meaning that other methods can not be used to define a particle with a spheroidal morphology.

[0026] In this invention "**solid compound C**" refers to a substance or mixture of solid substances, selected from a drug, explosive, colorant, pigment, cosmetic, polymer, catalyst, chemical product for the agriculture or other particle or substance completely insoluble in water, and susceptible to being dissolved at the pressure at which the value of supersaturation ( $\beta$ ) is less than or equal to 1, where the temperature is within the margins described later according to the invention.

[0027] The formation of micro- or nanoparticles can be monitored and controlled by analysing the turbidity of the system, in turn induced by successive pressure changes and mole fraction of  $\text{CO}_2$  ( $X_{\text{CO}_2}$ ) in the system. The turbidity of the system can be measured by optic density. The optic density (OD) is defined as the absorbance of an optic element at a determined wavelength in which the system does not absorb, and by unit of optical path or distance. The optical density is a property used in the invention to detect variations of the supersaturation value ( $\beta$ ) in the system when  $\beta \geq 1$ , and of the supramolecular organization of its components. The "on-line" monitoring of the system is done by means of a UV visible Spectrophotometer.

#### Detailed Description of the Invention

[0028] According to the first aspect of this invention, a process is provided to obtain micro- or nanoparticles with a homogenous structure.

[0029] The process according to the first aspect of the invention comprises:

a) preparing in a closed container a mixture that includes an organic solvent or a mixture of organic solvents, a solid compound C and water (H<sub>2</sub>O), where in said stage a) there are at least one liquid phase and one solid phase, **characterized in that** it also comprises:

b) adding a fluid B to said mixture prepared in stage a) so that the pressure of the container is increased until to reach to a first pressure (P<sub>1</sub>), allowing said addition of fluid B at said first pressure (P<sub>1</sub>) to prepare a microemulsion of an organic phase saturated with water,

where there is no solid phase in this stage and where at said first pressure (P<sub>1</sub>) the value of the predetermined supersaturation (β) of the solid compound C is lower to or equal to 1,

wherein said fluid B is a fluid which at atmospheric pressure and room temperature is a gas and which at a first pressure (P<sub>1</sub>), greater than atmospheric pressure, is miscible with the organic solvent, and immiscible or partially miscible with water, and it is not a supercritical fluid at any stage,

c) varying said first pressure (P<sub>1</sub>) to a second pressure (P<sub>2</sub>), where said variation in pressure is different from zero (ΔP ≠ 0), and where at said second pressure (P<sub>2</sub>) said water (H<sub>2</sub>O) has an anti-solvent effect which cause the precipitation of solid micro- or nanoparticles of compound C with homogenous structure;

where in said stage c) there are at least one liquid phase and one solid phase; and, if desired;

d) collecting at said second pressure (P<sub>2</sub>) said solid micro- or nanoparticles by conventional methods.

**[0030]** In said stages a), b) and c), the transition from one to another is determined by the phase changes observed through variations in the optic density.

**[0031]** Thus, in stages a) and c), the nature of the solvent will determine the existence of one or more liquid phases, depending on if it is a polar or non-polar organic solvent or mixtures of both or of more than one of them. In said stages a) and c) when a polar solvent is used there is a unique liquid phase. If a non-apolar solvent is used, there will be more than one liquid phases determined by optic density.

**[0032]** Advantageously, the mixture of stage a) is prepared at atmospheric pressure and room temperature. However, the temperature of the process, regardless of the stage, can be comprised between -50°C and 200°C, and yet more preferably between 20°C and 50°C.

**[0033]** Optionally, stages a) and b) can be carried out simultaneously. In this embodiment, where stages a) and b) are carried out simultaneously, the process continues to stage c). The increase in pressure of the container to the first pressure (P<sub>1</sub>) in stage b) can be carried out whether by adding fluid B, the use of mechanical means such as, e.g., a piston inside the container, or by adding an inert gas, such as for example N<sub>2</sub>. Also, the pressure

variation in stage c) to a second pressure (P<sub>2</sub>) can be done in the same way.

**[0034]** In yet another embodiment of this invention, in stage a) a surfactant can also be added. Advantageously, the presence of the surfactant in the microemulsion obtained in stage b) improves the stability of the final dispersion even more, which is capable of favouring the control of the nucleation processes and crystalline growth, thus, obtaining still smaller particle sizes and narrower size distributions.

**[0035]** It is worth pointing out that in stage b), when said first pressure (P<sub>1</sub>) is reached, where the supersaturation value (β) the ratio between the concentration [C] of the solid compound C to the concentration of the supersaturation [C<sub>s</sub>] of said solid compound C in the microemulsion:

$$\beta = [C]/[C_s] \dots 1$$

where said microemulsion is formed by said organic solvent or mixture of organic solvents, said water (H<sub>2</sub>O) and said fluid B and, optionally, a surfactant.

**[0036]** The microemulsion formed in said stage b) comprises an organic phase saturated with water, where said organic phase is formed by said fluid B, said organic solvent or a mixture of organic solvents and said solid compound C and optionally, said surfactant.

**[0037]** The variation of the first pressure (P<sub>1</sub>) to the second pressure (P<sub>2</sub>), where said positive or negative pressure variation, i.e., increasing or decreasing the first pressure (P<sub>1</sub>) to a second pressure (P<sub>2</sub>), stimulates the precipitation of the solid micro- or nanoparticles of homogenous structure due to the anti-solvent effect of the water (H<sub>2</sub>O) at said second pressure (P<sub>2</sub>), where the supersaturation value (β) is greater than 1.

**[0038]** Surprisingly, the authors of this invention have found that the final characteristics of the micro- or nanoparticles obtained do not depend in the effectiveness of agitation as is the case in the technologies described to date, but rather the degree of homogenous distribution of water in the microemulsion obtained which after a variation in the pressure (stage c)) causes the water to act as an anti-solvent and causes the precipitation of the solid micro- or nanoparticles. Therefore, the process of this invention represents a considerable change in the line followed up to now for obtaining finely divided particles based mostly in that a higher agitation or homogenization of the solution that contains the solid to be precipitated provides a smaller sized particle.

**[0039]** According to the present invention, the anti-solvent effect of water in determined pressure conditions and in an adequate medium, a microemulsion, allows to obtain solid micro- or nanoparticles of a homogenous structure whose micro- or nanoparticles also manifest the initial properties of the nature of the organic com-

pound to be precipitated.

**[0040]** In an embodiment of the invention, when the pressure variation in stage c) is positive, i.e.  $\Delta P > 0$ , the second pressure ( $P_2$ ) is greater than the first pressure ( $P_1$ ), and the precipitation is a reversible phenomenon.

**[0041]** In another embodiment of the invention, when the pressure variation in stage c) is negative, i.e.  $\Delta P < 0$ , the second pressure ( $P_2$ ) is lower than the first pressure ( $P_1$ ) and the precipitation is an irreversible phenomenon.

**[0042]** According to the process of the invention, when  $\Delta P > 0$  the organic solvent can be selected from a polar or non-polar solvent and when  $\Delta P < 0$  the organic solvent is a polar solvent.

**[0043]** Next, the micro- or nanoparticles are collected at said second pressure ( $P_2$ ) by conventional means. Optionally, said particles can be isolated and collected, e.g., by filtration and also when  $\Delta P < 0$  they can be collected over a water current so that a suspension of said particles is obtained. Said suspension has application in the preparation of a medicine preferably by oral, intravenous or mucosal administration.

**[0044]** With the pressure variation (stage c) of the microemulsion the behaviour of the water is modified, which goes from acting as a solvent at  $P_1$  to acting as an anti-solvent at  $P_2$  which causes the precipitation of the solid micro- or nanoparticles with a homogenous structure. In an embodiment of the invention, said solid micro- or nanoparticles are also crystalline. Also, in another embodiment of this invention said solid micro- or nanoparticles have an aspect ratio considerably equal to the unity (1).

**[0045]** Advantageously, with the process according to the first aspect of the invention micro- or nanoparticles are provided with an excellent aspect ratio-property. Thus, with the process of the invention micro- or nanoparticles with improved structural characteristics can be obtained such as, e.g., a greater crystallinity, which confers greater stability during storage, fluidity and less tendency to absorb humidity.

**[0046]** Furthermore, adding fluid B, for example  $\text{CO}_2$  in the process of the invention and unlike those of the techniques described to date, does not cause the precipitation of the solid compound C in the form of finely divided particles.

**[0047]** With it, the process of the invention provides a new technology for obtaining solid micro- or nanoparticles where fluid B is not responsible for the precipitation, nor is it used in supercritical state in any stage of the process. It is believed that the anti-solvent effect of water at  $P_2$  and the conditions in which the precipitation occurs favour a nucleation and growth of crystalline structure with a substantially spheroidal morphology. Thus, the new process provides unexpected properties to the micro- or nanoparticles obtained, properties not described in the state of the art at said micro- or nanoscale.

**[0048]** The crystallinity, and therefore, the absence of an amorphous solid in, e.g. a pharmaceutical product is of great importance because it is considered that formulas that contain amorphous forms are less stable than

the crystalline solid and, therefore, carry a risk regarding its preservation of the properties of the material during storage. These partial or completely amorphous materials usually have greater reactivity and are unstable to mechanical and thermal stress and have a greater tendency to absorb water.

**[0049]** Furthermore, advantageously, according to the first aspect of this invention, a process for obtaining micro- or nanoparticles with a considerably spheroidal morphology, also called morphology with an aspect ratio close to 1, according to the method mentioned in the definitions section for aspect ratio.

**[0050]** Morphology is a highly determining property in the preparation and administration of, for example, a medicine which already has special effect in the properties of pharmaceutical formulation such as fluidity and compactness. Thus, the more regular and similar to the spherical form is the morphology of the particles the greater their fluidity in aerosol formulas, such as the ones used for oral administration.

**[0051]** The particles obtained have a narrow volumetric size distribution and an average associated sphere diameter of less than 10  $\mu\text{m}$ , generally less than 1  $\mu\text{m}$ . Advantageously, the size of the particle obtained with the process defined in the invention is comprised between 10  $\mu\text{m}$  and 500 nm, preferably between 3  $\mu\text{m}$  and 800 nm, more preferable between 1  $\mu\text{m}$  and 700 nm.

**[0052]** Thus, according to the second aspect of the invention, the micro- or nanoparticles obtained according to the first aspect of the invention are of a great interest in the preparation of a composition which also comprises other acceptable pharmaceutical excipients where the structure and morphology of the micro- or nanoparticles is a determining factor for their application.

**[0053]** Also, according to the third aspect of the invention said micro- or nanoparticles obtained are of special interest in the preparation of an aerosol for inhaled administration of medicines destined to the treatment of pulmonary diseases, or of other formulas where the purpose is to increase the bioavailability of active substances with low water solubility.

#### Description of the Drawings

**[0054]** Figure 1 shows two curves of supersaturation with regards to time (t), curve A and curve B.

**[0055]** Said figure 1 has three different areas, area I where there is no crystal growth, area II where there is crystal growth but no nucleation and area III where there is nucleation. Curve A corresponds to a qualitative profile of supersaturation corresponding to a process of crystallization where the nucleation phenomenon is favoured above the crystal growth process. Curve B corresponds to a qualitative profile of supersaturation of a process where the crystal growth is favoured above the nucleation.

**[0056]** The process of the invention follows a supersaturation type A curve, which is characterized in that

it takes place in area III in a brief period of time and, therefore, there is a high nucleation, with translates into a greater number of solid particles with a smaller size.

**[0057]** Figure 2 shows a facility to carry out the process of the invention. Said facility comprises a tank 1 which contains CO<sub>2</sub>, said tank is connected to a pump 3 to supply said liquid CO<sub>2</sub> at high pressure. The adding of liquid CO<sub>2</sub> over the mixing reactor 7 where there is already a mixture of organic solvent (or a mixture of organic solvents), a solid compound C and water can be done through the uppermost part through valves 4 and 6, or through valves 4 and 5 through the lower part. Through valves 9 and 5, the addition to the mixing reactor 7 of an inert gas N<sub>2</sub>, which is in tank 8, is controlled. This inert gas can be used to increase the pressure from P<sub>1</sub> to P<sub>2</sub> when  $\Delta P_{(P_2 > P_1)} > 0$ . Alternatively, a piston mechanically or pneumatically actuated (not shown) can be used to increase the pressure in mixing reactor 7. The microemulsion formed in reactor 7 at pressure P<sub>2</sub> passes to filter 11 through valve 10, where it undergoes the first filtration maintaining the pressure P<sub>2</sub>. Upon exiting filter 11 and passing through valve 12, the microemulsion containing CO<sub>2</sub> is expanded and is rapidly depressurized to atmospheric pressure, with the consequent precipitation of the solid crystalline particles. During the filtration at atmospheric pressure in filter 13, the particles are retained in filter 13 and the mother liquor is collected in container 15 through valve 14.

**[0058]** Figure 3 shows the variation in optic density observed in a microemulsion formed according with the process of the invention, e.g., by the system "ibuprofen/acetone/water/PEG6000/CO<sub>2</sub>" in function of the pressure at 35°C.

**[0059]** The optical density is defined as the absorbance of an optic element at a determined wavelength and by unit of optical path or distance. The turbidity of a system is defined in terms of optical density when the system does not absorb light at that wavelength.

**[0060]** Figure 4 represents a differential scanning calorimetry profile (DSC) of the solid compound C (ibuprofen) obtained according to the process of the invention, with or without a surfactant (PEG6000). From said figure it can be observed that the presence of the surfactant does not modify the crystalline structure of the solid micro- or nanoparticles nor does it affect it if  $\Delta P_{(P_2 > P_1)} < 0$  or if  $\Delta P_{(P_2 > P_1)} > 0$ . Profile 1 corresponds to the ibuprofen compound obtained for  $\Delta P_{(P_2 > P_1)} > 0$ . in the presence of surfactant (PEG6000). Profiles 2 and 3 correspond to the ibuprofen compound obtained for  $\Delta P_{(P_2 > P_1)} < 0$  with or without surfactant (PEG6000), respectively. Profile 4 corresponds to the original unprocessed ibuprofen. In Figure 4 symbols X and Y correspond to the fusion endothermic peaks of the surfactant (PEG6000) and compound C (ibuprofen), respectively.

**[0061]** Figure 5 represents a X-ray diffraction spectrum of solid compound C (ibuprofen) obtained using the process of the invention in presence or absence of surfactant (PEG6000). Particularly, in said figure it can be

observed that with the process according to the invention, solid crystalline micro- or nanoparticles are obtained whether  $\Delta P_{(P_2 > P_1)} < 0$  or  $\Delta P_{(P_2 > P_1)} > 0$ . The spectrums (a) and (b) correspond to the ibuprofen compound obtained for  $\Delta P_{(P_2 > P_1)} < 0$  with or without surfactant (PEG6000), respectively. Spectrum (c) corresponds to the ibuprofen compound obtained for  $\Delta P_{(P_2 > P_1)} > 0$  with surfactant (PEG6000). Spectrum (d) corresponds to the original unprocessed ibuprofen compound.

**[0062]** Figure 6A is an image of a scanning electron microscope (SEM) of the ibuprofen compound obtained without surfactant and  $\Delta P < 0$  ( $P_2 < P_1$ ).

- Ibuprofen/acetone/water/CO<sub>2</sub>, without surfactant;
- Precipitation obtained at P<sub>2</sub> = atmospheric pressure
- X<sub>CO<sub>2</sub></sub>=0,16 (molar fraction of CO<sub>2</sub>);
- Solid collected in a non-pressurized filter;
- Average diameter of particle: 740 nm;
- Total output of the solid collected: 86%.

**[0063]** Figure 6B is an image of a scanning electron microscope (SEM) of the ibuprofen compound obtained with PEG6000 and  $\Delta P < 0$  ( $P_2 < P_1$ ).

- Ibuprofen/acetone/water/CO<sub>2</sub>/PEG6000;
- Precipitation obtained at P<sub>2</sub> = atmospheric pressure
- X<sub>CO<sub>2</sub></sub>=0,16 (molar fraction of CO<sub>2</sub>);
- Solid collected in a non-pressurized filter;
- Average diameter of particle: 680 nm;
- Total output of the solid collected: 81%.

**[0064]** From comparing Figures 6A and 6B it can be observed that with  $\Delta P < 0$  the presence of the surfactant influences the size of the particle, reducing it with its presence.

**[0065]** Figure 6C is an image of a scanning electron microscope (SEM) of the ibuprofen compound obtained with PEG6000 and  $\Delta P > 0$  ( $P_2 > P_1$ ).

- Ibuprofen/acetone/water/CO<sub>2</sub>/PEG6000;
- Precipitation obtained at P<sub>2</sub>=147 bars and 35°C;
- X<sub>CO<sub>2</sub></sub>=0,16 (molar fraction of CO<sub>2</sub>);
- Solid collected in a non-pressurized filter;
- Average diameter of particle: 935 nm;

**[0066]** Below, preferred embodiments of this invention are described, without limiting.

## Examples

**Example 1:** Obtaining nanoparticles of ibuprofen through the process of the invention when  $\Delta P < 0$  (without surfactant)

**[0067]** In a mixing reactor 7 of 300mL capacity, 170 mL of a solution of the ibuprofen compound in acetone with a relative concentration to saturation of 63% and 90mL of H<sub>2</sub>O, obtaining a suspension of the drug in the

acetone-water mixture. Over this suspension CO<sub>2</sub> is added with a volume of flow of 7Kg/hr until the pressure P<sub>1</sub> of reactor 7 reaches the 100Bar. The temperature is kept constant throughout the entire process at 35°C. At these conditions, this system is formed by a transparent microemulsion consisting of the system ibuprofen/acetone/water/CO<sub>2</sub>. The microemulsion is left to stabilize at P<sub>1</sub> and 35°C during 15 minutes (see Figure 2). The supply of CO<sub>2</sub> is closed and the adding of N<sub>2</sub> begins through the uppermost part of the reactor through valve 6, to maintain the pressure P<sub>1</sub> constant at 100 bar within the reactor during the depressurization process of the microemulsion. The depressurization of the microemulsion from P<sub>1</sub> to P<sub>2</sub>=1bar, with the consequent rapid evaporation of CO<sub>2</sub>, is done through the opening of a valve 12. The evaporation of CO<sub>2</sub> causes the water to again manifest its new anti-solvent characteristic over the dissolved ibuprofen in the organic phase, causing its precipitation. The precipitated particles are collected in filter 13 at P<sub>2</sub>=1bar (atmospheric pressure). The precipitated particles are washed with CO<sub>2</sub> at 40Bar. The mother liquors are collected in container 15 through valve 14. The size of the particle of the ibuprofen compound was determined through a scanning electron microscope (SEM). The distribution of particle sizes of the collected solid phase in filter 13 have an average of 740 nm with a standard deviation of 100 nm. It was observed through X-ray powder diffraction that the particles obtained are crystalline, and by using the scanning electron microscope (SEM) that they have a homogenous spheroidal morphology (see Figure 5A). The output of the process is of 86%.

[0068] Optionally, there is a second filter to collect the possible solids that did not dissolve in the microemulsion obtained at pressure P<sub>1</sub>; said filter is represented in Figure 2 as filter 11.

**Example 2: Obtaining nanoparticles of ibuprofen through the process of the invention when  $\Delta P < 0$  (in presence of a surfactant PEG6000 dissolved in the aqueous phase)**

[0069] In a mixing reactor 7 of 300mL capacity, 170mL of a solution of the ibuprofen compound in acetone with a relative concentration of 63% and 90mL of an aqueous solution which contains 10% in weight of the surfactant PEG6000, are introduced, obtaining a suspension of the drug in the acetone-water mixture. Over this suspension CO<sub>2</sub> is added with a volume of flow of 7Kg/hr until the pressure P<sub>1</sub> of reactor 7 reaches 100bar. The temperature is kept constant throughout the entire process at 35°C. At these conditions, this system is formed by a transparent microemulsion consisting of the system ibuprofen/acetone/water/PEG6000/CO<sub>2</sub>. The microemulsion is left to stabilize at P<sub>1</sub> and 35°C during 15 minutes (see Figure 2). The supply of CO<sub>2</sub> is closed and the adding of N<sub>2</sub> begins through the uppermost part of the reactor 7 through valve 6, to maintain the pressure P<sub>1</sub> constant at 100Bars within the reactor during the depressurization

process of the microemulsion. The depressurization of the microemulsion from P<sub>1</sub> to P<sub>2</sub>=1Bar, with the consequent rapid evaporation of CO<sub>2</sub>, is done through the opening of a valve 12. The evaporation of CO<sub>2</sub> causes the water to again manifest its new anti-solvent characteristic over the dissolved ibuprofen in the organic phase, causing its precipitation. The precipitated particles are collected in filter 13 at P<sub>2</sub>=1bar (atmospheric pressure). The precipitated particles are washed with CO<sub>2</sub> at 40Bar. The mother liquors are collected in container 15 through valve 14. The size of the particle of the ibuprofen compound was determined through a scanning electron microscope (SEM). The distribution of particle sizes of the collected solid phase in filter 13 have an average of 680nm with a standard deviation of 110nm. It was observed through X-ray powder diffraction that the particles obtained are crystalline, and by using the scanning electron microscope (SEM) that they have a homogenous spheroidal morphology (see Figure 5B). The output of the process is of 81%.

[0070] Optionally, there is a second filter to collect the possible solids that did not dissolve in the microemulsion obtained at pressure P<sub>1</sub>; said filter is represented in Figure 2 as filter 11.

**Example 3: Obtaining nanoparticles of ibuprofen through the process of the invention when  $\Delta P > 0$  (without surfactant)**

[0071] In a mixing reactor 7 of 300mL capacity, 170mL of a solution of the ibuprofen compound in acetone with a relative concentration of 63% and 90mL of H<sub>2</sub>O are introduced, obtaining a suspension of the drug in the acetone-water mixture. Over this suspension CO<sub>2</sub> is added with a volume of flow of 7Kg/hr until the pressure P<sub>1</sub> of reactor 7 reaches 100bar. The temperature is kept constant throughout the entire process at 35°C. At these conditions, this system is formed by a transparent microemulsion consisting of the system ibuprofen/acetone/water/CO<sub>2</sub>. The microemulsion is left to stabilize at P<sub>1</sub> and 35°C during 15 minutes (see Figure 2). The supply of CO<sub>2</sub> is closed and the adding of N<sub>2</sub> begins through the uppermost part of the reactor 7 through valve 6, until a pressure P<sub>2</sub>=146Bar within the reactor (P<sub>2</sub>>P<sub>1</sub>) is reached. The increase in pressure from P<sub>1</sub> to P<sub>2</sub> stimulates the water to again manifest its new anti-solvent effect over the solute present in the system solute/organic solvent/water/CO<sub>2</sub>, causing its precipitation. The precipitated solid is filtered over filter 11 at pressure P<sub>2</sub>. The precipitation of the mother liquors is done through valve 12 and they are collected in tank 15, after passing through filter 13 and valve 14. The solid collected in filter 11 is washed with CO<sub>2</sub> at 40Bar. The size of the particle of the ibuprofen compound was determined through a scanning electron microscope (SEM). The distribution of particle sizes of the collected solid phase in filter 11 have an average of 940nm with a standard deviation of 300nm. It was observed through X-ray powder diffraction that the

particles obtained are crystalline, and by using the scanning electron microscope (SEM) that they have a homogeneous spheroidal morphology. The output of the process is of 20%.

**Example 4:** Obtaining nanoparticles of ibuprofen through the process of the invention when  $\Delta P > 0$  (in presence of a surfactant PEG6000 dissolved in the aqueous phase)

**[0072]** In a mixing reactor 7 of 300mL capacity, 170mL of a solution of the ibuprofen compound in acetone with a relative concentration of 63% and 90mL of an aqueous solution which contains 10% in weight of surfactant PEG6000, are introduced, obtaining a suspension of the drug in the acetone-water mixture. Over this suspension  $\text{CO}_2$  is added with a volume of flow of 7Kg/hr until the pressure  $P_1$  of reactor 7 reaches 100bar. The temperature is kept constant throughout the entire process at 35°C. At these conditions, this system is formed by a transparent microemulsion consisting of the system ibuprofen / acetone / water / PEG6000 /  $\text{CO}_2$ . The microemulsion is left to stabilize at  $P_1$  and 35°C during 15 minutes (see Figure 2). The supply of  $\text{CO}_2$  is closed and the adding of  $\text{N}_2$  begins through the uppermost part of the reactor 7 through valve 6 until a pressure  $P_2 = 146\text{Bar}$  within the reactor ( $P_2 > P_1$ ) is reached. The increase in pressure from  $P_1$  to  $P_2$  stimulates the water to again manifest its new anti-solvent effect over the solute present in the system solute/organic solvent/water/PEG6000/ $\text{CO}_2$ , causing its precipitation. The precipitated solid is filtered over filter 11 at pressure  $P_2$ . The precipitation of the mother liquors is done through valve 12 and they are collected in tank 15, after passing through filter 13 and valve 14. The solid collected in filter 11 is washed with  $\text{CO}_2$  at 40Bar. The size of the particle of the ibuprofen compound was determined through a scanning electron microscope (SEM). The distribution of particle sizes of the collected solid phase in filter 11 have an average of 935nm with a standard deviation of 460nm. It was observed through X-ray powder diffraction that the particles obtained are crystalline, and by using the scanning electron microscope (SEM) that they have a homogeneous spheroidal morphology. The output of the process is of 21%. (See Figure 6C)

## Claims

1. Process for obtaining solid micro- or nanoparticles which comprises:

a) preparing in a closed container a mixture that includes an organic solvent or a mixture of organic solvents, a solid compound C and water ( $\text{H}_2\text{O}$ ), where in said stage a) there are at least one liquid phase and one solid phase, **character-**

**ized in that** it also comprises:

b) adding a fluid B to said mixture prepared in stage a) so that the pressure of the container is increased until to reach a first pressure ( $P_1$ ), allowing said addition of fluid B at said first pressure ( $P_1$ ) to prepare a microemulsion of an organic phase saturated with water, where there is no solid phase in this stage and where at said first pressure ( $P_1$ ) the value of the predetermined supersaturation ( $\beta$ ) of the solid compound C is lower to or equal to 1, wherein said fluid B is a fluid which at atmospheric pressure and room temperature is a gas and which at a first pressure ( $P_1$ ), greater than atmospheric pressure, is miscible with the organic solvent, and immiscible or partially miscible with water, and it is not a supercritical fluid at any stage,  
c) varying said first pressure ( $P_1$ ) to a second pressure ( $P_2$ ), where said variation in pressure is different from zero ( $\Delta P \neq 0$ ), and where at said second pressure ( $P_2$ ) said water ( $\text{H}_2\text{O}$ ) has an anti-solvent effect which cause the precipitation of solid micro- or nanoparticles of compound C with homogenous structure; where in said stage c) there are at least one liquid phase and one solid phase; and, if desired;  
d) collecting at said second pressure ( $P_2$ ) said solid micro- or nanoparticles by conventional methods.

2. Process according to claim 1, where said stages a) and b) are carried out simultaneously.

3. Process according to any of the previous claims, where in stage a) the mixture includes a surfactant.

4. Process according to claim 1, where in stage a) said container is at atmospheric pressure and room temperature.

5. Process according to claim 1, where in stage c) said variation is such that the second pressure ( $P_2$ ) is greater than ( $P_1$ ), ( $\Delta P > 0$ ).

6. Process according to claim 5, where said stage c) is reversible, i.e., the precipitation is a reversible phenomenon.

7. Process according to claim 1, where in stage c) said variation is such that the second pressure ( $P_2$ ) is lower than the first pressure ( $P_1$ ), ( $\Delta P < 0$ ).

8. Process according to claim 1, where when  $\Delta P > 0$  said organic solvent is selected among a polar or non-polar solvent.

9. Process according to claim 1, where when  $\Delta P < 0$  said

organic solvent is a polar solvent.

10. Process according to claim 1, where said solid compound C is insoluble or partially insoluble in H<sub>2</sub>O. 5
11. Process according to claim 1, where said fluid B is CO<sub>2</sub>. 10
12. Process according to claim 1, where said solid micro- or nanoparticles have a particle size of less than 10 µm, preferably of less than 1 µm. 15
13. Process according to claim 1, where said solid micro- or nanoparticles have an aspect ratio value close to the unity (1). 20
14. Process according to claim 13, where said micro- or nanoparticles have a substantially spheroidal morphology. 25
15. Process according to any of the previous claims, where given that solid compound C has a crystalline nature said micro- or nanoparticles obtained have a crystalline structure. 30
16. Composition which comprises said solid micro- or nanoparticles obtained according to any of the previous claims for preparing formulas together with other acceptable pharmaceutical excipients. 35
17. Use of said solid micro- or nanoparticles obtained according to any of claims 1 to 15 for the manufacture of a medicine for oral administration in aerosol form. 40
18. Use of said solid micro- or nanoparticles obtained according to any of claims 1 to 15 for manufacture of a suspension for oral intravenous or mucosal administration. 45

## Patentansprüche

1. Verfahren zum Erhalten fester Mikro- oder Nanoteilchen, das folgenden Schritt aufweist:
  - a) Herstellen einer Mischung, die ein organisches Lösungsmittel oder eine Mischung organischer Lösungsmittel, eine feste Verbindung C und Wasser (H<sub>2</sub>O) umfasst, in einem geschlossenen Behälter, wobei es bei Schritt a) zumindest eine flüssige Phase und eine feste Phase gibt, **dadurch gekennzeichnet, dass** dasselbe außerdem folgenden Schritt aufweist:
  - b) Zugeben eines Fluids B zu der Mischung, die bei Schritt a) hergestellt wird, so dass der Druck des Behälters ansteigt, bis er einen ersten Druck (P<sub>1</sub>) erreicht, was es ermöglicht, dass die Zuga-

be des Fluids B bei dem ersten Druck (P<sub>1</sub>) eine Mikroemulsion einer organischen Phase, die mit Wasser gesättigt ist, herstellt, wobei es bei diesem Schritt keine feste Phase gibt, und wobei bei dem ersten Druck (P<sub>1</sub>) der Wert der vorbestimmten Übersättigung (β) der festen Verbindung C kleiner oder gleich 1 ist, wobei das Fluid B ein Fluid ist, das bei Umgebungsdruck und Raumtemperatur ein Gas ist, und das bei einem ersten Druck (P<sub>1</sub>), der höher als der Umgebungsdruck ist, mit dem organischen Lösungsmittel mischbar ist und mit Wasser unmischbar oder teilweise mischbar ist, und bei keinem Schritt ein überkritisches Fluid ist, c) Variieren des ersten Drucks (P<sub>1</sub>) zu einem zweiten Druck (P<sub>2</sub>), wobei die Variation des Drucks sich von null unterscheidet ( $\Delta \neq 0$ ), und wobei bei dem zweiten Druck (P<sub>2</sub>) das Wasser (H<sub>2</sub>O) einen Anti-Lösungsmittel-Effekt besitzt, der die Ausfällung fester Mikro- oder Nanoteilchen der Verbindung C mit homogener Struktur bewirkt; wobei es bei Schritt c) zumindest eine flüssige Phase und eine feste Phase gibt; und, falls erwünscht: d) Sammeln der festen Mikro- oder Nanoteilchen bei dem zweiten Druck (P<sub>2</sub>) durch herkömmliche Verfahren.

2. Verfahren gemäß Anspruch 1, bei dem die Schritte a) und b) gleichzeitig ausgeführt werden.
3. Verfahren gemäß einem der vorherigen Ansprüche, bei dem bei Schritt a) die Mischung ein oberflächenaktives Mittel umfasst.
4. Verfahren gemäß Anspruch 1, bei dem sich bei Schritt a) der Behälter bei Umgebungsdruck und Raumtemperatur befindet.
5. Verfahren gemäß Anspruch 1, bei dem bei Schritt c) die Variation derart ist, dass der zweite Druck (P<sub>2</sub>) größer ist als (P<sub>1</sub>), ( $\Delta P > 0$ ).
6. Verfahren gemäß Anspruch 5, bei dem Schritt c) umkehrbar ist, d.h. die Ausfällung ist ein umkehrbares Phänomen.
7. Verfahren gemäß Anspruch 1, bei dem bei Schritt c) die Variation derart ist, dass der zweite Druck (P<sub>2</sub>) niedriger ist als der erste Druck (P<sub>1</sub>), ( $\Delta P < 0$ ).
8. Verfahren gemäß Anspruch 1, bei dem, wenn  $\Delta P > 0$  gilt, das organische Lösungsmittel unter einem polaren oder einem nicht-polaren Lösungsmittel ausgewählt wird.
9. Verfahren gemäß Anspruch 1, bei dem, wenn  $\Delta P < 0$

gilt, das organische Lösungsmittel ein polares Lösungsmittel ist.

10. Verfahren gemäß Anspruch 1, bei dem die feste Verbindung C in  $H_2O$  unlöslich oder teilweise unlöslich ist. 5
11. Verfahren gemäß Anspruch 1, bei dem das Fluid B  $CO_2$  ist. 10
12. Verfahren gemäß Anspruch 1, bei dem die festen Mikro- oder Nanoteilchen eine Teilchengröße von weniger als  $10\ \mu m$ , vorzugsweise weniger als  $1\ \mu m$  aufweisen. 15
13. Verfahren gemäß Anspruch 1, bei dem die festen Mikro- oder Nanoteilchen einen Aspektverhältniswert aufweisen, der nahe bei Eins (1) liegt. 20
14. Verfahren gemäß Anspruch 13, bei dem die Mikro- oder Nanoteilchen im Wesentlichen eine Kugel-Morphologie aufweisen. 25
15. Verfahren gemäß einem der vorhergehenden Ansprüche, bei dem unter der Annahme, dass die feste Verbindung C kristalliner Natur ist, die Mikro- oder Nanoteilchen, die erhalten werden, eine kristalline Struktur aufweisen. 30
16. Zusammensetzung, die die festen Mikro- oder Nanoteilchen aufweist, die gemäß einem der vorherigen Ansprüche erhalten werden, zum Herstellen von Formeln, gemeinsam mit anderen annehmbaren pharmazeutischen Hilfsstoffen. 35
17. Verwendung der festen Mikro- oder Nanoteilchen, die gemäß einem der Ansprüche 1 bis 15 erhalten werden, für die Herstellung eines Arzneimittels zur oralen Verabreichung in Aerosol-Form. 40
18. Verwendung der festen Mikro- oder Nanoteilchen, die gemäß einem der Ansprüche 1 bis 15 erhalten werden, zur Herstellung einer Suspension zur oralen, intravenösen oder Schleimhaut-Verabreichung. 45

## Revendications

1. Procédé pour obtenir des micro-particules ou des nano-particules solides, comprenant les étapes consistant à : 50
  - a) préparer dans un récipient fermé un mélange contenant un solvant organique ou un mélange de solvants organiques, un composé solide C et de l'eau ( $H_2O$ ), 55
  - dans lequel, à ladite étape a), il y a au moins une phase liquide et une phase solide ; **carac-**

**térisé en ce qu'il** comprend en outre les étapes suivantes:

b) ajouter un fluide B audit mélange préparé à l'étape a), de telle sorte que la pression du récipient soit accrue jusqu'à atteindre une première pression ( $P_1$ ), permettant audit ajout de fluide B à ladite première pression ( $P_1$ ) de préparer une micro-émulsion d'une phase organique saturée avec de l'eau, dans lequel il n'y a pas de phase solide dans cette étape, et dans lequel, à ladite première pression ( $P_1$ ), la valeur de la sursaturation prédéterminée ( $\beta$ ) du composé solide C est inférieure ou égale à 1, dans lequel ledit fluide B est un fluide qui, à la pression atmosphérique et à la température ambiante, est un gaz et qui, à une première pression ( $P_1$ ) supérieure à la pression atmosphérique, est miscible avec le solvant organique et est immiscible ou partiellement miscible avec l'eau, et n'est un fluide supercritique dans aucune étape,

c) faire varier ladite première pression ( $P_1$ ) jusqu'à une deuxième pression ( $P_2$ ), dans lequel ladite variation de pression est différente de zéro ( $\Delta P \neq 0$ ), et dans lequel, à ladite deuxième pression ( $P_2$ ), ladite eau ( $H_2O$ ) présente un effet antisolvant qui entraîne la précipitation de micro-particules ou nano-particules du composé C avec une structure homogène ; dans lequel, à ladite étape c), il y a au moins une phase liquide et une phase solide ; et, si on le souhaite :

d) collecter, à ladite deuxième pression ( $P_2$ ), les dites micro-particules ou nano-particules solides en utilisant des procédés conventionnels.

2. Procédé selon la revendication 1, dans lequel lesdites étapes a) et b) sont exécutées simultanément.
3. Procédé selon l'une quelconque des revendications précédentes dans lequel, à l'étape a), le mélange contient un agent tensioactif.
4. Procédé selon la revendication 1 dans lequel, à l'étape a), ledit récipient se trouve à la pression atmosphérique et à température ambiante.
5. Procédé selon la revendication 1 dans lequel, à l'étape c), ladite variation est telle que la deuxième pression ( $P_2$ ) soit supérieure à ( $P_1$ ), ( $\Delta P > 0$ ).
6. Procédé selon la revendication 5 dans lequel ladite étape c) est réversible, c'est-à-dire que la précipitation est un phénomène réversible.
7. Procédé selon la revendication 1 dans lequel, à l'étape c), ladite variation est telle que la deuxième pres-

sion ( $P_2$ ) soit inférieure à la première pression ( $P_1$ ), ( $\Delta P < 0$ ).

8. Procédé selon la revendication 1 dans lequel, lorsque  $\Delta P > 0$ , ledit solvant organique est sélectionné parmi un solvant polaire ou non polaire. 5
9. Procédé selon la revendication 1 dans lequel, lorsque  $\Delta P < 0$ , ledit solvant organique est un solvant polaire. 10
10. Procédé selon la revendication 1 dans lequel ledit composé solide C est insoluble ou partiellement insoluble dans l'eau ( $H_2O$ ). 15
11. Procédé selon la revendication 1 dans lequel ledit fluide B est le  $CO_2$ .
12. Procédé selon la revendication 1 dans lequel lesdites micro-particules ou nano-particules solides présentent une taille de particule qui est inférieure à 10  $\mu m$ , de préférence inférieure à 1  $\mu m$ . 20
13. Procédé selon la revendication 1 dans lequel lesdites micro-particules ou nano-particules solides présentent une valeur de rapport d'éclatement qui est proche de l'unité (1). 25
14. Procédé selon la revendication 13 dans lequel lesdites micro-particules ou nano-particules présentent une morphologie sensiblement sphéroïdale. 30
15. Procédé selon l'une quelconque des revendications précédentes dans lequel, étant donné que le composé solide C présente une nature cristalline, lesdites micro-particules ou nano-particules obtenues présentent une structure cristalline. 35
16. Composition comprenant lesdites micro-particules ou nano-particules solides obtenues selon l'une quelconque des revendications précédentes pour préparer des formules de concert avec d'autres excipients pharmaceutiques acceptables. 40
17. Utilisation desdites micro-particules ou nano-particules solides obtenues selon l'une quelconque des revendications 1 à 15 pour fabriquer un médicament pour administration par voie orale sous la forme d'un aérosol. 45
18. Utilisation desdites micro-particules ou nano-particules solides obtenues selon l'une quelconque des revendications 1 à 15 pour fabriquer une suspension pour une administration par voie orale, intraveineuse ou muqueuse. 50 55

FIG 1







FIG 2




**FIG 3**




**FIG 4**




**FIG 5**




**FIG 6A**



**FIG 6B**



**FIG 6C**



## REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

### Patent documents cited in the description

- US 4582731 A [0005]
- WO 9965469 A [0007]
- WO 9714407 A [0007]
- US 2004071781 A [0011]
- WO 2007072106 A [0011]
- WO 2004110603 A [0012]

### Non-patent literature cited in the description

- **N. RASENACK ; B. W. MÜLLER.** *Pharmaceutical Research*, 2002, vol. 19, 1894-1900 [0004]
- **M. CHAROENCHAITRAKOOL ; F. DEGHANI ; N. R. FOSTER.** *Ind. Eng. Chem. Res.*, 2000, vol. 39, 4794-4802 [0005]
- **D. HERMSDORF ; STEPHAN JAUER ; R. SIGNORELL.** *Molecular Physics*, 2007, vol. 105 (8), 951-959 [0006]
- **P. PATHAK ; M.J. MEZIANI ; T. DESAI ; Y.-P. SUN.** *J. Supercrit. Fluids*, 2006, vol. 37, 279-286 [0007]
- **J. ZHANG ; B. HAN ; X. ZHANG ; J. HE ; Z. LIU ; T. JIANG ; G. YANG.** *Chem Eur. J.*, 2002, vol. 8 (17), 3879 [0010]
- **C.A. FERNANDEZ ; C.M. WAI.** *Small*, 2006, vol. 2 (11), 1266 [0012]
- **S.ALMEIDA-PRIETO ; J. BLANCO-MENDEZ ; F.J. OTERO-ESPINAR.** *European journal of Pharmaceutics and Biopharmaceutics*, 2007, vol. 67, 766-776 [0025]